vs

Side-by-side financial comparison of BIOCRYST PHARMACEUTICALS INC (BCRX) and Kimco Realty (KIM). Click either name above to swap in a different company.

Kimco Realty is the larger business by last-quarter revenue ($558.0M vs $406.6M, roughly 1.4× BIOCRYST PHARMACEUTICALS INC). BIOCRYST PHARMACEUTICALS INC runs the higher net margin — 60.5% vs 29.8%, a 30.7% gap on every dollar of revenue. On growth, BIOCRYST PHARMACEUTICALS INC posted the faster year-over-year revenue change (209.1% vs 4.0%). Over the past eight quarters, BIOCRYST PHARMACEUTICALS INC's revenue compounded faster (109.4% CAGR vs 5.6%).

BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China.

Kimco Realty Corporation, headquartered in Jericho, New York, is a real estate investment trust that invests in shopping centers.

BCRX vs KIM — Head-to-Head

Bigger by revenue
KIM
KIM
1.4× larger
KIM
$558.0M
$406.6M
BCRX
Growing faster (revenue YoY)
BCRX
BCRX
+205.1% gap
BCRX
209.1%
4.0%
KIM
Higher net margin
BCRX
BCRX
30.7% more per $
BCRX
60.5%
29.8%
KIM
Faster 2-yr revenue CAGR
BCRX
BCRX
Annualised
BCRX
109.4%
5.6%
KIM

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
BCRX
BCRX
KIM
KIM
Revenue
$406.6M
$558.0M
Net Profit
$245.8M
$166.3M
Gross Margin
97.7%
Operating Margin
64.0%
37.2%
Net Margin
60.5%
29.8%
Revenue YoY
209.1%
4.0%
Net Profit YoY
1017.5%
23.7%
EPS (diluted)
$1.13
$0.46

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BCRX
BCRX
KIM
KIM
Q1 26
$558.0M
Q4 25
$406.6M
$542.5M
Q3 25
$159.4M
$535.9M
Q2 25
$163.4M
$525.2M
Q1 25
$145.5M
$536.6M
Q4 24
$131.5M
$525.4M
Q3 24
$117.1M
$507.6M
Q2 24
$109.3M
$500.2M
Net Profit
BCRX
BCRX
KIM
KIM
Q1 26
$166.3M
Q4 25
$245.8M
$151.2M
Q3 25
$12.9M
$137.8M
Q2 25
$5.1M
$163.0M
Q1 25
$32.0K
$132.8M
Q4 24
$-26.8M
$166.0M
Q3 24
$-14.0M
$136.0M
Q2 24
$-12.7M
$119.7M
Gross Margin
BCRX
BCRX
KIM
KIM
Q1 26
Q4 25
97.7%
Q3 25
98.6%
Q2 25
98.3%
Q1 25
96.9%
Q4 24
95.4%
Q3 24
97.3%
Q2 24
98.4%
Operating Margin
BCRX
BCRX
KIM
KIM
Q1 26
37.2%
Q4 25
64.0%
36.4%
Q3 25
18.6%
34.9%
Q2 25
18.2%
39.2%
Q1 25
14.6%
33.6%
Q4 24
-3.4%
31.7%
Q3 24
6.6%
33.7%
Q2 24
8.0%
32.1%
Net Margin
BCRX
BCRX
KIM
KIM
Q1 26
29.8%
Q4 25
60.5%
27.9%
Q3 25
8.1%
25.7%
Q2 25
3.1%
31.0%
Q1 25
0.0%
24.8%
Q4 24
-20.4%
31.6%
Q3 24
-12.0%
26.8%
Q2 24
-11.6%
23.9%
EPS (diluted)
BCRX
BCRX
KIM
KIM
Q1 26
$0.46
Q4 25
$1.13
Q3 25
$0.06
Q2 25
$0.02
Q1 25
$0.00
Q4 24
$-0.13
Q3 24
$-0.07
Q2 24
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BCRX
BCRX
KIM
KIM
Cash + ST InvestmentsLiquidity on hand
$274.7M
Total DebtLower is stronger
Stockholders' EquityBook value
$-119.2M
$10.4B
Total Assets
$514.2M
$19.6B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BCRX
BCRX
KIM
KIM
Q1 26
Q4 25
$274.7M
$211.6M
Q3 25
$212.9M
$159.3M
Q2 25
$260.0M
$226.6M
Q1 25
$295.1M
$131.3M
Q4 24
$320.9M
$688.6M
Q3 24
$96.8M
$789.0M
Q2 24
$78.4M
$126.4M
Total Debt
BCRX
BCRX
KIM
KIM
Q1 26
Q4 25
$7.7B
Q3 25
Q2 25
Q1 25
Q4 24
$8.0B
Q3 24
Q2 24
Stockholders' Equity
BCRX
BCRX
KIM
KIM
Q1 26
$10.4B
Q4 25
$-119.2M
$10.4B
Q3 25
$-387.9M
$10.5B
Q2 25
$-421.6M
$10.5B
Q1 25
$-451.9M
$10.6B
Q4 24
$-475.9M
$10.7B
Q3 24
$-468.6M
$10.5B
Q2 24
$-475.6M
$10.6B
Total Assets
BCRX
BCRX
KIM
KIM
Q1 26
$19.6B
Q4 25
$514.2M
$19.7B
Q3 25
$446.4M
$19.9B
Q2 25
$457.2M
$19.8B
Q1 25
$480.0M
$19.7B
Q4 24
$490.4M
$20.3B
Q3 24
$491.3M
$20.1B
Q2 24
$472.4M
$19.5B
Debt / Equity
BCRX
BCRX
KIM
KIM
Q1 26
Q4 25
0.74×
Q3 25
Q2 25
Q1 25
Q4 24
0.75×
Q3 24
Q2 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BCRX
BCRX
KIM
KIM
Operating Cash FlowLast quarter
$292.0M
Free Cash FlowOCF − Capex
$291.2M
FCF MarginFCF / Revenue
71.6%
Capex IntensityCapex / Revenue
0.2%
Cash ConversionOCF / Net Profit
1.19×
TTM Free Cash FlowTrailing 4 quarters
$344.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BCRX
BCRX
KIM
KIM
Q1 26
Q4 25
$292.0M
$258.4M
Q3 25
$41.6M
$332.4M
Q2 25
$41.3M
$305.4M
Q1 25
$-27.5M
$223.8M
Q4 24
$-5.2M
$239.5M
Q3 24
$8.2M
$295.9M
Q2 24
$-1.4M
$294.1M
Free Cash Flow
BCRX
BCRX
KIM
KIM
Q1 26
Q4 25
$291.2M
Q3 25
$40.3M
Q2 25
$41.1M
Q1 25
$-27.7M
$205.4M
Q4 24
$-5.9M
Q3 24
$8.2M
Q2 24
$-1.5M
FCF Margin
BCRX
BCRX
KIM
KIM
Q1 26
Q4 25
71.6%
Q3 25
25.3%
Q2 25
25.2%
Q1 25
-19.0%
38.3%
Q4 24
-4.5%
Q3 24
7.0%
Q2 24
-1.4%
Capex Intensity
BCRX
BCRX
KIM
KIM
Q1 26
Q4 25
0.2%
0.0%
Q3 25
0.8%
0.0%
Q2 25
0.1%
0.0%
Q1 25
0.1%
3.4%
Q4 24
0.5%
Q3 24
0.1%
Q2 24
0.1%
Cash Conversion
BCRX
BCRX
KIM
KIM
Q1 26
Q4 25
1.19×
1.71×
Q3 25
3.23×
2.41×
Q2 25
8.12×
1.87×
Q1 25
-859.91×
1.69×
Q4 24
1.44×
Q3 24
2.18×
Q2 24
2.46×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BCRX
BCRX

Segment breakdown not available.

KIM
KIM

Revenues from rental properties, net$552.8M99%
Management and other fee income$5.2M1%

Related Comparisons